Navigation Links
Potentia Pharmaceuticals Appoints Johanna M. Seddon, M.D. and Janet Stoltz Sunness, M.D. to Scientific Advisory Board
Date:11/11/2008

LOUISVILLE, Ky., Nov. 11 /PRNewswire/ -- Potentia Pharmaceuticals, a privately held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD), announced today the appointments of Johanna M. Seddon, M.D. and Janet Stoltz Sunness, M.D. to its Scientific Advisory Board effective November 6, 2008.

Dr. Seddon is a world known macular degeneration specialist and pioneer in nutritional and genetic research in age-related macular degeneration, as well as an international leader in the field of ophthalmic epidemiology. For more than 20 years Dr. Seddon has directed NIH-based research on epidemiologic, biologic, and genetic biomarkers for macular degeneration and has made original contributions in these areas. Dr. Seddon is Professor of Ophthalmology at Tufts University School of Medicine and founding director of the Ophthalmic Epidemiology & Genetics Service at the New England Eye Center. She was a vice president and trustee of ARVO, and the recipient of the inaugural Maurice F. Rabb, Jr. Award from Prevent Blindness America, for dedication and contributions to prevention and treatment of age-related macular degeneration.

Dr. Sunness is an accomplished researcher in understanding how diseases cause loss of vision and has directed several National Institutes of Health-funded studies in this field. Currently, Dr. Sunness is a medical director at Hoover Services for Low Vision and Blindness at the Greater Baltimore Medical Center. Her clinical practice focuses on low vision and on retinal and macular disease. An ophthalmologist by training, Dr. Sunness is a leading world expert on geographic atrophy, the advanced dry form of age-related macular degeneration and has also pioneered new methods of measuring visual function. Dr. Sunness is also a leading world expert on how pregnancy affects the mother's eyes, both in cases of pre-existing conditions like diabetes as well as when diseases develop during pregnancy.

"We are very fortunate to have individuals of Dr. Seddon's and Dr. Sunness' standing and knowledge join Potentia's Scientific Advisory Board," said Cedric Francois, M.D., Ph.D., President and Chief Executive Officer for Potentia. "They are both extremely accomplished and held in very high regard in their fields. Their valuable insights and expertise will be of great value as we continue to develop our drug candidate, POT-4, which we believe holds great promise as a leading drug candidate in the treatment of both dry and wet AMD."

About AMD

AMD is the leading cause of blindness in the elderly of the western world and affects more than 10 million patients in the United States alone. The current standard of care for AMD relies primarily on angiogenesis inhibitors, an approach geared towards the approximately 10-15% of AMD patients with complications resulting from ocular angiogenesis (growth of new blood vessels and bleeding in the back of the eye). No drug currently on the market has been approved for the treatment of the remaining patients, who suffer from the so-called "dry" form of the disease.

About the Complement System and POT-4

Complement activation is an inflammatory process involving dozens of plasma proteins, ultimately leading to cell membrane disruption through the membrane attack complex (MAC). Activation of the complement system is an important part of the body's defensive immune response against pathogens such as bacteria and viruses. In spite of its defensive function, inappropriate or excessive complement activation can have destructive consequences if left unchecked. Over the past three years, multiple scientific publications have strongly linked variants of genes encoding components of the complement system with a predisposition toward AMD.

POT-4 binds tightly to complement component C3, preventing its participation in the complement activation cascade. As C3 is the central component of all major complement activation pathways, its inhibition effectively shuts down downstream complement activation that could otherwise lead to local inflammation, tissue damage and upregulation of angiogenic factors such as vascular endothelial growth factors (VEGF).

About Potentia

Potentia Pharmaceuticals, Inc. is an early stage biotechnology company focused on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases, with an initial emphasis on diseases of the eye such as age-related macular degeneration.


'/>"/>
SOURCE Potentia Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. RVX-208 Exploratory Study Illustrates Early Potential for Alzheimers Disease
2. Potentia Pharmaceuticals Drug Candidate for Age-Related Macular Degeneration Shows Positive Safety Profile in Phase I Clinical Trial
3. The Medicare Hospital-Acquired Conditions Initiative Will Spur Increased Patient Screening and Potentially Increased Antibiotic Use
4. Potentia Pharmaceuticals to Present ASaP Phase I Clinical Trial Data for POT-4 at the American Academy of Ophthalmology Annual Meeting
5. Innovation and Strong Therapeutic Potential Seen in Adult Stem Cells, According to Frost & Sullivan
6. Jellyfish Protein Shows Potential to Help With Memory
7. CPC of America, Inc. to Explore Strategic Alternatives; Appoints FTI Capital Advisors to Assess Potential Opportunities
8. Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants
9. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
10. Rosetta Genomics and the National Institute of Health (NIH) to Identify Potential MicroRNA Drug Targets for HIV
11. Self-assembling polymer arrays improve data storage potential
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , ... October 12, 2017 , ... ... Wound Market with the addition of its newest module, US Hemostats & Sealants. ... for thrombin hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and biologic sealants used ...
(Date:10/11/2017)... ... October 11, 2017 , ... At its national board meeting ... I. Sheikh, the co-founder, CEO and chief research scientist of Minnesota-based Advanced Space ... membership in ARCS Alumni Hall of Fame . ASTER Labs is a ...
(Date:10/11/2017)... Alto, CA, USA (PRWEB) , ... October 11, 2017 , ... ... set to take place on 7th and 8th June 2018 in San Francisco, CA. ... policy influencers as well as several distinguished CEOs, board directors and government officials from ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 ... London (ICR) and University of ... prognostic tool to risk-stratify patients with multiple myeloma (MM), in ... nine . The University of Leeds ... by Myeloma UK, and ICR will perform the testing services ...
Breaking Biology Technology:
(Date:7/20/2017)... -- Delta (NYSE: DAL ) customers now can use fingerprints ... Washington National Airport (DCA). ... Delta launches biometrics to board aircraft at Reagan Washington National ... Delta,s biometric boarding pass experience that launched ... into the boarding process to allow eligible Delta SkyMiles Members who are ...
(Date:5/16/2017)... N.J. , May 16, 2017  Veratad Technologies, ... provider of online age and identity verification solutions, announced ... K(NO)W Identity Conference 2017, May 15 thru May 17, ... Regan Building and International Trade Center. ... the globe and in today,s quickly evolving digital world, ...
(Date:4/18/2017)...  Socionext Inc., a global expert in SoC-based imaging and computing ... M820, which features the company,s hybrid codec technology. A demonstration utilizing ... Inc., will be showcased during the upcoming Medtec Japan at Tokyo ... Las Vegas Convention Center April 24-27. ... Click here for an image ...
Breaking Biology News(10 mins):